Category: Latest News
-
Better Home & Finance shares drop after pricing of public stock offering
Better Home & Finance Holding Company (NASDAQ:BETR) shares declined about 14% after the company revealed the pricing details of an underwritten public offering of 1,875,000 shares of its Class A common stock. The transaction is expected to raise roughly $60 million in gross proceeds before deducting underwriting discounts and commissions. The company has also granted…
-
U.S. defense stocks decline after ceasefire, report signals smaller war funding request
Several U.S. defense companies moved lower in premarket trading on Wednesday after the ceasefire agreement between the United States and Iran, while a media report indicated the Pentagon may seek substantially less war funding than previously planned. According to The Washington Post, citing U.S. officials and people familiar with the discussions, the administration is preparing…
-
Delta tops Q1 forecasts but issues softer-than-expected profit outlook
Delta Air Lines (NYSE:DAL) reported first-quarter earnings on Wednesday that exceeded analyst expectations, although its profit forecast for the current quarter came in below market projections. Delta shares had already rallied ahead of the results, supported by a broader market rebound following news of a U.S.-Iran ceasefire that drove oil prices lower and lifted airline…
-
Beasley Broadcasting shares surge as quarterly loss comes in narrower than feared
Beasley Broadcast Group (NASDAQ:BBGI) reported fourth-quarter results showing a smaller-than-anticipated loss, even as the traditional radio advertising market continues to face pressure. The announcement sparked a dramatic reaction in the market, with the company’s shares jumping about 111.53% in pre-market trading. Investors appeared to focus on Beasley’s operational improvements and progress on restructuring its debt…
-
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment
Plus Therapeutics Inc. (NASDAQ:PSTV) said the U.S. Food and Drug Administration has granted Orphan Drug Designation to REYOBIQ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas. The FDA awarded the designation for malignant glioma more broadly than the company had initially sought, extending it to include pediatric ependymoma. Pediatric malignant gliomas are rare…
-
Nurix Therapeutics shares edge higher despite Q1 earnings miss
Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported fiscal first-quarter 2026 results on Wednesday that came in below analyst expectations. Despite the miss, the clinical-stage biotech company’s shares rose about 3.06% in pre-market trading as investors focused on the progress of its drug development pipeline and its strong cash reserves. Nurix posted an adjusted loss of $0.79 per…
-
Hovnanian shares gain after $200M homebuilding partnership with GTIS
Hovnanian Enterprises (NYSE:HOV) shares climbed about 4% on Wednesday after a report from Bloomberg said the homebuilder had entered a $200 million joint venture with GTIS Partners LP. The partnership establishes a pooled investment structure aimed at developing and selling residential properties. Under the arrangement, New York–based GTIS will provide $150 million in capital, while…
-
Xcel Brands shares slip as losses continue despite cost-cutting efforts
Xcel Brands, Inc. (NASDAQ:XELB) reported a fourth-quarter adjusted loss of $0.32 per share on revenue of $1.2 million as the media and consumer products company continues restructuring its business model. Revenue was unchanged from the same quarter a year earlier and sharply lower than the $8.3 million reported for the full year 2024. The results…
-
Adagio Medical secures FDA clearance to broaden ventricular ablation study
Adagio Medical Holdings Inc. (NASDAQ:ADGM) said it has received Investigational Device Exemption (IDE) authorization from the U.S. Food and Drug Administration to expand its FULCRUM-VT clinical trial assessing the company’s next-generation vCLAS Ultra-Low Temperature Ablation Ventricular Ablation System for the treatment of Sustained Monomorphic Ventricular Tachycardia. The approval enables Adagio to launch a clinical sub-study…
-
Rubrik chosen as preferred cybersecurity partner by American Hospital Association
Rubrik (NYSE:RBRK) said it has been designated a preferred cybersecurity provider by the American Hospital Association, a move that gives the data protection firm access to nearly 5,000 member hospitals across the United States. Through the designation, Rubrik will be able to offer cyber resilience solutions, data protection services, ransomware preparedness training and financial risk…